Genmab partner gets approval for lung cancer drug from Duobody platform

Janssen Pharmaceuticals has received approval for lung cancer drug Rybrevant

Photo: Joost Melis / Genmab / PR

On Friday, Genmab's partner Janssen Pharmaceuticals has been granted approval to launch lung cancer drug Rybrevant from the US Food and Drug Administration (FDA).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs